91奇迹

 找回密码
 中文注册
楼主: 小路

有5月世界肺癌大会的最新信息吗?

[复制链接]
发表于 2008-5-31 15:33:09 | 显示全部楼层 来自: 美国
<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowlight"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32793.html">Randomized,
phase II trial comparing carboplatin (C) and tri-weekly paclitaxel (tP)
with C and weekly paclitaxel (wP) in elderly patients (pts) with
advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>M. Maemondo </h4></td><td width="1%" valign="top"><h4>19046</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32908.html">Effect of ciprofloxacin on the systemic exposure to erlotinib.</a></td><td width="1%" valign="top"><h4>H. Kletzl </h4></td><td width="1%" valign="top"><h4>19047</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33917.html">Interferon alpha + 13-cis-retinoic acid modulation of BCL-2 + paclitaxel for recurrent SCLC.</a></td><td width="1%" valign="top"><h4>J. Aisner </h4></td><td width="1%" valign="top"><h4>19048</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30543.html">Cisplatin
(CDDP) plus vinorelbine (NVB) as first-line treatment for advanced
non-small-cell lung cancer (NSCLC): Retrospective analysis to improve
the patient's convenience on day 8 NVB administration.</a></td><td width="1%" valign="top"><h4>M. Provencio </h4></td><td width="1%" valign="top"><h4>19049</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33878.html">hase
I/II study of S-1 combined with gemcitabine in elderly patients with
advanced non-small cell lung cancer: Thoracic Oncology Research Group
(TORG) 0502.</a></td><td width="1%" valign="top"><h4>T. Seto </h4></td><td width="1%" valign="top"><h4>19050</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32545.html">Impact of intrathoracic (IT) metastases upon survival in stage IV non small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. Husain </h4></td><td width="1%" valign="top"><h4>19051</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33394.html">hase 1/2 trial of MKC-1 and pemetrexed in patients (pts) with advanced NSCLC.</a></td><td width="1%" valign="top"><h4>T. Hoang </h4></td><td width="1%" valign="top"><h4>19052</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33083.html">harmacokinetic and pharmacodynamics (PK/PD) approach for myelosupressions of amrubicin (AMR) in patients with lung cancer.</a></td><td width="1%" valign="top"><h4>T. Kimura </h4></td><td width="1%" valign="top"><h4>19054</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_36055.html">DGFR
inhibition using imatinib (I) combined with docetaxel (D), a potential
new treatment strategy in the treatment of recurrent non-small cell
lung cancer (NSCLC): Preliminary efficacy results.</a></td><td width="1%" valign="top"><h4>C. H. Huang </h4></td><td width="1%" valign="top"><h4>19055</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33354.html">hase
I/II trial of TS-1 plus carboplatin in patients with advanced non-small
cell lung cancer: Final report of a Central Japan Lung Study Group
Trial-CJLSG0402.</a></td><td width="1%" valign="top"><h4>H. Saka </h4></td><td width="1%" valign="top"><h4>19056</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31863.html">The DISTAL-2 phase III randomized trial of single agent weekly docetaxel (wD) <i>vs</i>
wD plus gemcitabine (G) or vinorelbine (V) vs wD plus capecitabine (X)
as second-line treatment of advanced non-small-cell lung cancer (NSCLC)
patients (pts).</a></td><td width="1%" valign="top"><h4>V. Gebbia </h4></td><td width="1%" valign="top"><h4>19057</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32579.html">Outcomes of second line chemotherapy (II-LC) in platinum resistant non small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>D. Tassinari </h4></td><td width="1%" valign="top"><h4>19058</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30992.html">egylated
liposomal anti-eIF3c shRNA-vinorelbine tartrate formulation (SEVINA-V)
inhibits oncogenic protein translational initiation, and oncogene
addiction inducing PCD type I, II, and III in NSCLC chemoresistant to
taxanes.</a></td><td width="1%" valign="top"><h4>J. Giannios </h4></td><td width="1%" valign="top"><h4>19059</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35458.html">hase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC).</a></td><td width="1%" valign="top"><h4>A. Dowlati </h4></td><td width="1%" valign="top"><h4>19060</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31094.html">Gemcitabine
and oxaliplatin (GEMOX), a promissing combination for the treatment of
relapsed, advanced or metastatic non small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>C. J. Calfa </h4></td><td width="1%" valign="top"><h4>19061</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33431.html">Evaluation
of mini nutritional assessment (MNA) in metastatic lung cancer
patients: Correlation of laboratory values indicating malnutrition,
inflammation, and cachexia with clinical data.</a></td><td width="1%" valign="top"><h4>I. Gioulbasanis </h4></td><td width="1%" valign="top"><h4>19062</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33868.html">Twelve-year retrospective analysis of lung cancer--The TYROL Study: Daily routine in 1,424 patients (1995-2006).</a></td><td width="1%" valign="top"><h4>M. Fiegl </h4></td><td width="1%" valign="top"><h4>19063</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35951.html">Vinorelbine plus oxaliplatin in unfit patients (pts) with stage IV non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>O. Mir </h4></td><td width="1%" valign="top"><h4>19064</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34151.html">ERCC1
and beta tubulin class III (BT-III) expression by quantitative
immunofluorescence (IF) in the responder and non-responder group of
patients with advanced non-small-cell lung cancer after 2 cycles of
cisplatin (P) and vinorelbine (Vn) chemotherapy.</a></td><td width="1%" valign="top"><h4>S. Park </h4></td><td width="1%" valign="top"><h4>19065</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34503.html">The relationship between change in tumor size and survival in advanced NSCLC treated with gefitinib.</a></td><td width="1%" valign="top"><h4>J. X. Wu </h4></td><td width="1%" valign="top"><h4>19066</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31341.html">The impact of tumor histology on survival among elderly chemotherapy-treated patients with stage IIIB/IV NSCLC.</a></td><td width="1%" valign="top"><h4>K. Clements </h4></td><td width="1%" valign="top"><h4>19067</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32832.html">Oral
vinorelbine (NVBO) and gemcitabine (GEM) in elderly patients with
advanced non-small-cell lung cancer (NSCLC): A phase II study conducted
by the Galician Lung Cancer Group (GLCG).</a></td><td width="1%" valign="top"><h4>J. L. Fírvida </h4></td><td width="1%" valign="top"><h4>19068</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30492.html">Effects
of chemotherapy and zoledronic acid on bone metabolism measured by the
osteoclast specific TRAP level in patient with bone metastases due to
lung cancer.</a></td><td width="1%" valign="top"><h4>G. Rabinowits </h4></td><td width="1%" valign="top"><h4>19069</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33327.html">A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer.</a></td><td width="1%" valign="top"><h4>M. Fukuda </h4></td><td width="1%" valign="top"><h4>19070</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35211.html">CEA response as a prognostic marker in non-small-cell lung carcinoma (NSCLC) patients treated with gefitinib or erlotinib.</a></td><td width="1%" valign="top"><h4>J. Ceballos </h4></td><td width="1%" valign="top"><h4>19071</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34127.html">Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation.</a></td><td width="1%" valign="top"><h4>H. Kim </h4></td><td width="1%" valign="top"><h4>19072</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33680.html">hase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC).</a></td><td width="1%" valign="top"><h4>D. Shipley </h4></td><td width="1%" valign="top"><h4>19073</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34692.html">The relationship between circulating VEGF level and outcome of advanced Chinese NSCLC treated with gefitinib.</a></td><td width="1%" valign="top"><h4>Y. Y. Zhao </h4></td><td width="1%" valign="top"><h4>19074</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34665.html">EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>V. Moiseyenko </h4></td><td width="1%" valign="top"><h4>19075</h4></td></tr></tbody></table>
有爱,就有奇迹!
发表于 2008-5-31 15:34:47 | 显示全部楼层 来自: 美国
<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowdark"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30646.html">Bronchial carcinoid tumours: Clinical features and management in a series of 45 patients.</a></td><td width="1%" valign="top"><h4>R. Srirajaskanthan </h4></td><td width="1%" valign="top"><h4>19076</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34154.html">A
phase II, multicenter evaluation of docetaxel, gemcitabine, and
bevacizumab followed by bevacizumab alone in patients with locally
advanced or metastatic non-small cell lung cancer (central localization
excluded).</a></td><td width="1%" valign="top"><h4>R. H. Ansari </h4></td><td width="1%" valign="top"><h4>19077</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35340.html">A phase II study of weekly irinotecan and carboplatin for previously untreated extensive disease small cell lung cancer.</a></td><td width="1%" valign="top"><h4>T. Mio </h4></td><td width="1%" valign="top"><h4>19078</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34029.html">A
phase II clinical and PET study of erlotinib and bexarotene for heavily
pretreated advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>K. H. Dragnev </h4></td><td width="1%" valign="top"><h4>19079</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34826.html">Management of bone metastases from lung cancer: Consensus recommendations from an international panel.</a></td><td width="1%" valign="top"><h4>K. Nackaerts </h4></td><td width="1%" valign="top"><h4>19080</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33262.html">hase
I trial of the novel epothilone sagopilone (ZK-EPO) in combination with
cisplatin as first-line therapy in patients with extensive-disease
small-cell lung cancer (ED-SCLC).</a></td><td width="1%" valign="top"><h4>T. C. Gauler </h4></td><td width="1%" valign="top"><h4>19081</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_36087.html">The population alteration of CD11b<sup>+</sup>/CD14<sup>-</sup>
myeloid-derived suppressor cells in patients with advanced stage,
non-small cell lung cancer and the clinical relevance to the
responsiveness to epidermal growth factor receptor (EGFR) tyrosi.</a></td><td width="1%" valign="top"><h4>Y. Wang </h4></td><td width="1%" valign="top"><h4>19082</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_36132.html">Erlotinib
for metastatic non-small cell lung cancer (mNSCLC): First, second or
third line setting--Does it matter? A single institution experience.</a></td><td width="1%" valign="top"><h4>S. Ailawadhi </h4></td><td width="1%" valign="top"><h4>19083</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_36323.html">A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>M. Gutierrez </h4></td><td width="1%" valign="top"><h4>19084</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31947.html">hase II trial of single agent oral vinorelbine in elderly (<u>&gt;</u>70 years) patients with advanced non small cell lung cancer and poor performance status.</a></td><td width="1%" valign="top"><h4>D. Amoroso </h4></td><td width="1%" valign="top"><h4>19085</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34181.html">hase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma.</a></td><td width="1%" valign="top"><h4>E. Hare </h4></td><td width="1%" valign="top"><h4>19086</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35924.html">A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma.</a></td><td width="1%" valign="top"><h4>. M. Bedano </h4></td><td width="1%" valign="top"><h4>19087</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32435.html">Is the platinum-based chemotherapy necessary for elderly patients with advanced non-small cell lung cancer (NSCLC)?</a></td><td width="1%" valign="top"><h4>H. Daga </h4></td><td width="1%" valign="top"><h4>19088</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32839.html">hase
II study of first line combination therapy with pegylated liposomal
doxorubicin (PLD) and carboplatin in patients (pts) with extensive
disease small cell lung cancer(ED SCLC).</a></td><td width="1%" valign="top"><h4>D. A. Vorobiof </h4></td><td width="1%" valign="top"><h4>19089</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_36298.html">hase
II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in
chemonaive non-small cell lung cancer (NSCLC) patients (pts).</a></td><td width="1%" valign="top"><h4>M. B. Lustberg </h4></td><td width="1%" valign="top"><h4>19090</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30456.html">Interim
safety analysis of a phase II study of erlotinib (E) alone or combined
with fulvestrant (F) in previously treated patients with advanced
non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>E. B. Garon </h4></td><td width="1%" valign="top"><h4>19091</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35118.html">First-line
chemotherapy with planned sequential administration of gemcitabine (G)
followed by docetaxel (D) in elderly advanced non-small-cell lung
cancer (NSCLC) patients: A multicenter phase II study.</a></td><td width="1%" valign="top"><h4>E. Vasile </h4></td><td width="1%" valign="top"><h4>19092</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35485.html">Lung cancer in HIV infection: A case series.</a></td><td width="1%" valign="top"><h4>G. Jung </h4></td><td width="1%" valign="top"><h4>19093</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33727.html">Economic
impact associated with the management of dermatologic adverse drug
reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer.</a></td><td width="1%" valign="top"><h4>T. Abraham </h4></td><td width="1%" valign="top"><h4>19094</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33581.html">hase
II study of sequential topoisomerase (Top) targeting regimens (reg)
with irinotecan/oxaliplatin (I/O) followed by etoposide/carboplatin
(E/Crb) in patients with extensive small cell lung cancer (SCLC).</a></td><td width="1%" valign="top"><h4>J. F. Rossman </h4></td><td width="1%" valign="top"><h4>19095</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35767.html">hase
II study to evaluate the efficacy and safety of bortezomib (PS-341) in
chemotherapy-na&#239;ve patients with advanced stage non-small cell lung
cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>L. Ho </h4></td><td width="1%" valign="top"><h4>19096</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34512.html">Biweekly
docetaxel and carboplatin as first-line therapy in patients with
advanced non-small cell lung cancer (NSCLC). Finally results of a phase
II study.</a></td><td width="1%" valign="top"><h4>J. L. Fírvida </h4></td><td width="1%" valign="top"><h4>19097</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35432.html">A
phase II study of erlotinib (E) in previously untreated elderly
patients (pts) with inoperable or advanced stage non-small cell lung
cancer (NSCLC) cancer and an ECOG PS 0-3.</a></td><td width="1%" valign="top"><h4>L. Rajdev </h4></td><td width="1%" valign="top"><h4>19098</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31827.html">Gemcitabine
(G) and cisplatin (C) in a modified 3-week schedule for non-small cell
lung cancer (NSCLC): Impact on hematologic toxicity and dose intensity
(DI).</a></td><td width="1%" valign="top"><h4>O. Caffo </h4></td><td width="1%" valign="top"><h4>19099</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33118.html">reliminary
safety and efficacy data of a phase II trial of vinflunine and
cetuximab in the second-line treatment of patients with advanced
non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>T. E. Stinchcombe </h4></td><td width="1%" valign="top"><h4>19100</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35754.html">A phase II clinical trial of gemcitabine and imatinib mesylate for patients with recurrent non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>M. Eleff </h4></td><td width="1%" valign="top"><h4>19101</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33362.html">ractice
pattern for patients receiving secondline treatment for non-small cell
lung cancer (NSCLC) with erlotinib in the community setting.</a></td><td width="1%" valign="top"><h4>L. J. Blakely </h4></td><td width="1%" valign="top"><h4>19102</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34592.html">Pemetrexed--Limitation of toxicity through supplementation treatment.</a></td><td width="1%" valign="top"><h4>A. Kehely </h4></td><td width="1%" valign="top"><h4>19104</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35063.html">A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)--Final report.</a></td><td width="1%" valign="top"><h4>M. A. Sovak </h4></td><td width="1%" valign="top"><h4>19105</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34763.html">Feasibility of treatment of relapsed NSCLC with accelerated pemetrexed given every 2 weeks.</a></td><td width="1%" valign="top"><h4>C. E. Emmanouilides </h4></td><td width="1%" valign="top"><h4>19106</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32742.html">Current
imaging techniques to detect brain metastasis and its findings in
correlation with histopathological diagnosis in african american
population with lung cancer.</a></td><td width="1%" valign="top"><h4>M. Kalavar </h4></td><td width="1%" valign="top"><h4>19107</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32324.html">Biweekly
docetaxel as first-line therapy in patients with advanced non-small
cell lung cancer (NSCLC) and performance status (PS) 2: A phase II
study of the Galician Lung Cancer Group.</a></td><td width="1%" valign="top"><h4>S. Vazquez-Estevez </h4></td><td width="1%" valign="top"><h4>19108</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34401.html">Bevacizumab
in combination with cisplatin and docetaxel as first line treatment of
patients (pts) with advanced or metastatic, non squamous,
non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>N. Ferrer </h4></td><td width="1%" valign="top"><h4>19109</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35092.html">A
phase I trial of sequential 2-weekly doublet therapy (SDT) of
gemcitabine (G) in combination with carboplatin (C) followed by
pemetrexed (P) in combination with gemcitabine in chemo-naive patients
with stage IIB/IV non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. P. Steele </h4></td><td width="1%" valign="top"><h4>19110</h4></td></tr></tbody></table>
有爱,就有奇迹!
发表于 2008-5-31 15:35:27 | 显示全部楼层 来自: 美国
<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr><td colspan="2"><table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowdark"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30967.html">hase II trial of weekly topotecan with docetaxel in recurrent small cell lung cancer (Aultman Lung 01).</a></td><td width="1%" valign="top"><h4>R. A. Khan </h4></td><td width="1%" valign="top"><h4>19111</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35987.html">atterns of PET/CT scan use in patients with advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>G. Franz </h4></td><td width="1%" valign="top"><h4>19112</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31431.html">A
phase II trial of alternating cycles of carboplatin/paclitaxel and
carboplatin/gemcitabine for stage IIIB/IV non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>I. Ahmad </h4></td><td width="1%" valign="top"><h4>19113</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31849.html">emetrexed in second-line treatment in advanced NSCLC: An experience on 131 patients.</a></td><td width="1%" valign="top"><h4>A. Bearz </h4></td><td width="1%" valign="top"><h4>19114</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34428.html">May
the istotype influence the response to pemetrexed in patients with non
small cell lung cancer? Preliminary data of our clinical experience.</a></td><td width="1%" valign="top"><h4>T. Franchina </h4></td><td width="1%" valign="top"><h4>19115</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34346.html">Effect of zoledronic acid combined with cisplatin for non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>Z. Gao </h4></td><td width="1%" valign="top"><h4>19116</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33068.html">EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>D. M. Kowalski </h4></td><td width="1%" valign="top"><h4>19117</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33851.html">Bronchioloalveolar lung CTCs retain cytomorphologic features of primary tumor type.</a></td><td width="1%" valign="top"><h4>D. Marrinucci </h4></td><td width="1%" valign="top"><h4>19118</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30772.html">hase I study of amrubicin and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.</a></td><td width="1%" valign="top"><h4>N. Yoshimura </h4></td><td width="1%" valign="top"><h4>19119</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31267.html">hase
II trial of alternate schedule of chemotherapy as front-line treatment
in metastatic non-small cell lung cancer (NSCLC): A single-centre
experience.</a></td><td width="1%" valign="top"><h4>R. López Castro </h4></td><td width="1%" valign="top"><h4>19120</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31553.html">Cost
effective chemotherapy (irinotecan and cisplatin) for treatment of lung
cancer in developing countries: Observations from India.</a></td><td width="1%" valign="top"><h4>D. Behera Prof (Dr)</h4></td><td width="1%" valign="top"><h4>19121</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31888.html">Whole brain radiotherapy with concurrent erlotinib for brain metastases from non-small cell lung cancer: A phase I study.</a></td><td width="1%" valign="top"><h4>J. S. Lind Drs</h4></td><td width="1%" valign="top"><h4>19122</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32219.html">Clinical significance of chemotherapy for small cell lung cancer (SCLC) with ECOG performance status (PS) 3-4.</a></td><td width="1%" valign="top"><h4>H. Kenmotsu </h4></td><td width="1%" valign="top"><h4>19123</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32732.html">Randomized,
phase II study of biweekly versus weekly paclitaxel/carboplatin (PC)
for the treatment of advanced non-small cell lung cancer: A Japan-Korea
collaborative clinical trial.</a></td><td width="1%" valign="top"><h4>K. Takayama </h4></td><td width="1%" valign="top"><h4>19124</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32904.html">Cutaneous
rash as a surrogate marker of time to tumor progression (TTP) with
erlotinib in previously treated advanced non- small cell lung cancer
(NSCLC).</a></td><td width="1%" valign="top"><h4>S. Cedrés Pérez </h4></td><td width="1%" valign="top"><h4>19125</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33009.html">Rh-endostatin
Injection plus paclitaxel and carboplatin therapy for non-small-cell
lung cancer: Randomized, double-blind, placebo-controlled, multicentre
study.</a></td><td width="1%" valign="top"><h4>B. Han Professor</h4></td><td width="1%" valign="top"><h4>19126</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33121.html">The efficacy and safety of loading dose ibandronate in the treatment of non-small cell lung cancer metastatic bone pain(MBP).</a></td><td width="1%" valign="top"><h4>S. Ren </h4></td><td width="1%" valign="top"><h4>19127</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34647.html">Treatment outcomes in patients with extensive stage small cell lung cancer - Experience from a tertiary Indian cancer centre.</a></td><td width="1%" valign="top"><h4>R. Bharath </h4></td><td width="1%" valign="top"><h4>19129</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35311.html">hase
II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy
for first line treatment of clinical stage IIIB or IV non-small cell
lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>L. Faoro </h4></td><td width="1%" valign="top"><h4>19130</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31288.html">Factors predicting silent brain metastases in patients with non-small-cell lung cancer.</a></td><td width="1%" valign="top"><h4>I. Na </h4></td><td width="1%" valign="top"><h4>19131</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31878.html">Effect of EGFR mutations on gefitinib in advanced previous treated non-small-cell lung cancer.</a></td><td width="1%" valign="top"><h4>J. Guo </h4></td><td width="1%" valign="top"><h4>19132</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32437.html">redictive effects of serum VEGF, TGF-a and EGFR mutations in advanced non-small cell lung cancer treated by erlotinib.</a></td><td width="1%" valign="top"><h4>S. Zhou </h4></td><td width="1%" valign="top"><h4>19133</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32244.html">A
phase I, dose escalation study to determine the maximum tolerated dose
of erlotinib when combined with pertuzumab in previously treated
non-small-cell lung cancer patients.</a></td><td width="1%" valign="top"><h4>E. Felip </h4></td><td width="1%" valign="top"><h4>19134</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33211.html">Concomitant treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib.</a></td><td width="1%" valign="top"><h4>S. Ma </h4></td><td width="1%" valign="top"><h4>19135</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34555.html">Clinical features of gefitinib-responders with non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>M. Shenglin </h4></td><td width="1%" valign="top"><h4>19136</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34866.html">emetrexed
monotherapy in patients with advanced non-small cell lung cancer who
have had prior chemotherapy: A prospective phase II trial.</a></td><td width="1%" valign="top"><h4>H. Lee </h4></td><td width="1%" valign="top"><h4>19137</h4></td></tr></tbody></table></td></tr><tr><td colspan="2"><img width="1" height="10" border="0" alt="" src="http://www.abstract.asco.org/abst_files/spacer.gif"/></td></tr><tr><td colspan="2"><h4><a href="http://www.abstract.asco.org/abst_files/AbstractDisclosureGrid08.pdf" target="_blank">Abs</a></h4></td></tr></tbody></table>
有爱,就有奇迹!
 楼主| 发表于 2008-6-1 08:18:14 | 显示全部楼层 来自: 中国上海
谢谢老友们的关心和支持!重返 易瑞萨只维持了一个月有效.射波刀一次4万.上海仅有华山有.
有爱,就有奇迹!
发表于 2008-6-2 04:17:44 | 显示全部楼层 来自: 加拿大
<h1>这是最近美国临床肿瘤协会(ASCO)第44届年度会议的消息,定于2008年5月30日至6月3日在麦考密克展览中心召开。我之所以贴这个贴子,是因为对里面谈的Erbitux药物不甚了解,似乎对肺癌有作用。敬请jimmy112199帮助关注一下6月3日后会议结果,我英语有限,烦请简单做个翻译。</h1><h1></h1><h1></h1><h1>ASCO 2008</h1><p>&nbsp;</p><p>The 44th ASCO annual meeting, set for May 30-June 3, 2008, McCormick Place, Chicago, Illinois, is likely, as always, to generate some exciting cancer stories. Some of the interesting upcoming&nbsp;research follows:</p><p>Eli Lilly are set to unveil data from more than 50 studies: The company will present the latest research findings on Alimta (pemetrexed for injection), Gemzar (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's thoracic cancer research. Of note is a pivotal Phase III study (ASCO Abstract # 8060) that has demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.</p><p>The drug Erbitux, from ImClone and Merck KGaA, is likely to cause some media and business interest as results from a new trial known as ‘Flex’ are announced. The trial, for treatment of lung cancer, has already been announced by Merck as a success, but the extent to which Erbitux improves survival is not yet known. Erbitux will go head to head with Genetech’s Avastin so trial results are especially important for the markets.</p><p><br/>Ipilimumab has shown increasing efficacy with time for melanoma patients, according to its manufacturers Medarex. Phase III trial results are to be announced.</p><p><br/>Avastin for first-line metastatic breast cancer patients is also set to garner attention with the announcement of key data from the ‘Avado’ trial, an ongoing randomized, double-blind, placebo-controlled, US, multicentre phase III trial that randomized 705 patients to receive docetaxel at a dose of 100 mg/m2 every 3 weeks with either placebo, Avastin at 7.5 mg/kg or Avastin at 15 mg/kg.</p><p><br/>Apart from drug trial announcements, the ASCO 2008 meeting will also provide a forum for the latest in medical engineering, genetics, epidemiology, palliative care and advice from patient advocacy groups and key opinion leaders alike.</p>
有爱,就有奇迹!
发表于 2008-6-2 07:14:06 | 显示全部楼层 来自: 加拿大
<span class="body_links"><span class="body_links"><a href="http://www.ascocancerfoundation.org/patient/ASCO+Resources/Research+and+Meetings/ASCO+Annual+Meetings/Lung+Cancer/Cetuximab+With+Chemotherapy+Helps+Patients+With+Advanced+Lung+Cancer+Live+Longer">Cetuximab With Chemotherapy Helps Patients With Advanced Lung Cancer Live Longer</a></span>
                <br/><span class="body_text"><i>June 1, 2008</i>
                        <br/>注:<span class="body_links"><span class="body_links"><a href="http://www.ascocancerfoundation.org/patient/ASCO+Resources/Research+and+Meetings/ASCO+Annual+Meetings/Lung+Cancer/Cetuximab+With+Chemotherapy+Helps+Patients+With+Advanced+Lung+Cancer+Live+Longer">Cetuximab</a>就是Erbitux.<div class="fyresult" id="contentout">上述文章题目是:&lt;cetuximab与化疗有助于晚期肺癌患者的寿命更长&gt; 2008.6.1</div><div class="fyresult" id="contentout">明白的朋友可参阅一下</div><div class="fyresult" id="contentout">我所知Erbitux是治结肠癌,中文名是爱必妥.</div></span></span></span></span>
有爱,就有奇迹!
发表于 2008-6-3 11:25:55 | 显示全部楼层 来自: LAN

爱必妥这东西

看起来爱必妥联合化疗比单纯的化疗能够延长病人生命1个多月。<br/><br/>有几个问题大家能讨论下吗?<br/>1. 爱必妥和特罗凯的机制似乎比较相似,不知道能不能作为特罗凯耐药后的选择<br/>2. 爱必妥的价格和用量如何呢?似乎是静脉注射的,要比口服麻烦些<br/>3. 副作用如何?<br/>
有爱,就有奇迹!
发表于 2008-6-4 03:06:11 | 显示全部楼层 来自: 美国
FLEX的随机多中心三期试药结果:第一 线治疗晚期非小细胞肺癌( NSCLC ) 爱必妥(cetuximab)联合顺铂/<font size="-1">诺维本</font>(CV)以及&#160; 仅用顺铂/<font size="-1">诺维本(</font>CV)的比较结果<br/><br/>子类别:转移性肺癌<br/>类别: 肺癌-转移性肺癌<br/>会议: 2008年asco年度会议<br/><br/>&#160;<br/>摘要: 3 <br/>引文: j临床肿瘤学26日: 2008年( 5月20日补编; abstr 3 ) <br/>作者:r. pirker等<br/>摘要: <br/><br/>&#160;<br/>背景:<br/>表皮生 长因子受体( EGFR )失 调在非小细胞肺癌及相关较差的预后中是常见的。这个三期的研究,评估表皮生长因子受体-有针对性的单克隆抗体cetuximab联合顺铂/<font size="-1">诺维本</font>( CV)相比,变异系数,在 晚期非小细胞肺癌疗效和安全性。<br/>方法:<br/>具有可 检测的表皮生长因子受体的晚期非小细胞肺癌患者被随机地,以 1比1比例分为两组,1组采用 爱必妥( cetuximab) ( 400 mg/m2初始剂量,然后 250 mg/m2/wk ) ,另加 顺铂(80 mg/m2 D1的)和 <font size="-1">诺维本</font>(25 mg/m2于D1 , D8级) q3w 。2组仅用顺铂/<font size="-1">诺维本</font> 。主要&#160; 终点是整体存活率( OS)。其次是士无&#160;&#160; 进展生存,肿瘤反应,疾病控制,和安全性。分&#160; 层随机是由ecog性能状态( 0 / 1比2 )和 肿瘤分期(湿&#160; iiib比四)。<br/>结果: <br/>1125年患者随机分组:A组 557人 ,B组 568 , 70 %为男性,年 龄中位数59 ( 18-83 )岁,有&#160;&#160; 94%的是四期, 47 %腺癌 , 34 %的鳞状细胞癌(鳞状细胞癌) , 83 % ecog 0 / 1 。生存分析是 868事件发生后。 A组整体存活率显着改善,(分&#160;&#160; 层Log - rank检验)。<br/>初步结果:<br/>预定小组分析显示白种人比亚洲人受益更大,且结果独立于组织学的不同和一般预后较好。分析 辅助终点正在进行中。<br/>结论:<br/>爱必妥加顺铂/<font size="-1">诺维本</font>对比顺铂/<font size="-1">诺维本显示</font>了优越的生存率<font size="-1"></font>,对于表皮生长因子受体可检测的非小细胞肺癌患者。在 亚洲人和白人之间,结果有显着差异。这是首次研究显示,爱必妥对表皮生长因子受体-有针对性的代理人在结合铂为基础的化疗在先进的第一线非小细胞肺癌,不论组织学和临床证实的相关<br/>cetuximab在非小细胞肺癌。 <br/>&#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 中位存活率(加爱必妥)&#160; 中位存活率(无爱必妥) &#160;&#160; HR(危险性比率)[ 95 % CI为] P值<br/>所有例( 1125) &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 11.3 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 10.1 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 0.871 [ 0.762 - 0.996 ] 0.0441 <br/>白种人例( 945 ) &#160;&#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 10.5 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160;&#160; 9.1 0.&#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 800 [ 0.692-0.924 ] 0.0025 <br/>与AC例( 412 ) &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 12.0 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 10.2 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 0.809 [ 0.644-1.016 ] 0.0673 <br/>与鳞状细胞癌( 347例) &#160;&#160;&#160; &#160;&#160;&#160; 10.2&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160; &#160; &#160; 8.9 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 0.794 [ 0.626-1.007 ] 0.0567 <br/>亚洲人例( 121 ) &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160;&#160; 17.6 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160;&#160; 20.4 &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; &#160;&#160;&#160; 1.179 [ 0.730 - 1.905 ] 0.4992 <br/><br/><h1>FLEX:<br/>A randomized, multicenter, phase III study of cetuximab in combination<br/>with cisplatin/vinorelbine (CV) versus CV alone in the first-line<br/>treatment of patients with advanced non-small cell lung cancer (NSCLC).</h1><table width="98%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td width="99%" valign="top"><table width="100%" cellspacing="3" cellpadding="0" border="0"><tbody><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Sub-category:</h3></td><td width="99%" valign="top"><h4><a href="http://www.abstract.asco.org/CatAbstView_55_49_AA.html">Metastatic Lung Cancer</a></h4></td></tr><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Category:</h3></td><td width="99%" valign="top"><h4>Lung Cancer--Metastatic Lung Cancer</h4></td></tr><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Meeting:</h3></td><td width="99%" valign="top"><h4><a href="http://www.abstract.asco.org/ConfCatView_55.html">2008 ASCO Annual Meeting</a></h4></td></tr></tbody></table></td><td width="1%" valign="top" nowrap="nowrap"><br/></td></tr></tbody></table><table width="98%" cellspacing="3" cellpadding="0" border="0"><tbody><tr><td colspan="2"><img width="1" height="10" border="0" alt="" src="http://www.abstract.asco.org/abst_files/spacer.gif"/></td></tr><tr><td id="vmtablerowdark" colspan="2"><img width="1" height="1" border="0" alt="" src="http://www.abstract.asco.org/abst_files/spacer.gif"/></td></tr><tr><td colspan="2"><img width="1" height="10" border="0" alt="" src="http://www.abstract.asco.org/abst_files/spacer.gif"/></td></tr><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Abstract No:</h3></td><td width="99%" valign="top"><h4>3</h4></td></tr><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Citation:</h3></td><td width="99%" valign="top"><h4><i>J Clin Oncol</i> 26: 2008 (May 20 suppl; abstr 3)</h4></td></tr><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Author(s):</h3></td><td width="99%" valign="top"><h4>R. Pirker, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, U. Gatzemeier, E. Bajeta, M. Emig, J. R. Pereira</h4></td></tr><tr><td width="1%" valign="top" nowrap="nowrap"><h3>Abstract:</h3></td><td width="99%" valign="top"><h4><p><b>Background:</b><br/>Epidermal growth factor receptor (EGFR) dysregulation is common in<br/>NSCLC and is associated with poorer prognosis. This phase III study<br/>assessed the efficacy and safety of the EGFR-targeted monoclonal<br/>antibody cetuximab in combination with cisplatin/vinorelbine (CV)<br/>compared with CV alone in advanced NSCLC. <b>Methods:</b> Patients with EGFR-detectable advanced NSCLC were randomized 1:1 to cetuximab (400 mg/m<sup>2 </sup>initial dose, then 250 mg/m<sup>2</sup>/wk) plus C (80 mg/m<sup>2</sup> d1) and V (25 mg/m<sup>2</sup><br/>d1, d8) q3w (arm A) or CV alone (arm B). The primary endpoint was<br/>overall survival (OS); secondary endpoints were progression-free<br/>survival, tumor response, disease control, and safety. Randomization<br/>was stratified by ECOG performance status (0/1 vs 2) and tumor stage<br/>(wet IIIb vs IV). <b>Results:</b> 1,125 patients were randomized: 557<br/>to arm A, 568 to arm B, 70% male, median age 59 (18-83) years, 94%<br/>stage IV, 47% adenocarcinoma (AC), 34% squamous cell carcinoma (SCC),<br/>83% ECOG 0/1. Survival analysis was performed after 868 events had<br/>occurred. OS was significantly improved in arm A (stratified log-rank<br/>test). Preliminary results of prespecified subgroup analyses suggest a<br/>greater benefit in Caucasians independent of histology and a general<br/>better prognosis in Asians. Analyses of secondary endpoints are<br/>ongoing. <b>Conclusions:</b> Cetuximab plus CV demonstrated superior<br/>survival over CV alone in patients with advanced EGFR-detectable NSCLC.<br/>There was a remarkable difference between the outcome of Asian and<br/>Caucasian patients. This is the first study to demonstrate a survival<br/>benefit of an EGFR-targeted agent in combination with platinum-based<br/>chemotherapy in advanced first-line NSCLC irrespective of histology and<br/>confirms the clinical relevance of cetuximab in NSCLC. <table cols="5" cellpadding="1" border="1" id="&amp;lcub;DEB4FE44–4138–480E-90F7–926FC316BDB8&amp;rcub;" class="DisplayTable" tgroupstyle="zlj-abs"><tbody><tr><td colspan="1" rowspan="1"><br/></td><td colspan="1" rowspan="1"><b>Median<br/>OS (mo)<br/>Arm A</b></td><td colspan="1" rowspan="1">Median<br/>OS (mo)<br/> Arm B</td><td colspan="1" rowspan="1">HR [95% CI]</td><td colspan="1" rowspan="1"><b>p-value</b></td></tr><tr><td colspan="1" rowspan="1"><b>All (n=1125)</b></td><td colspan="1" rowspan="1">11.3</td><td colspan="1" rowspan="1">10.1</td><td colspan="1" rowspan="1">0.871&#160;&#160;[0.762- 0.996]</td><td colspan="1" rowspan="1">0.0441</td></tr><tr><td colspan="1" rowspan="1"><b>Caucasians (n=945)</b></td><td colspan="1" rowspan="1">10.5</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">0.800&#160;&#160;[0.692-0.924]</td><td colspan="1" rowspan="1">0.0025</td></tr><tr><td colspan="1" rowspan="1"><b>with AC (n=412)</b></td><td colspan="1" rowspan="1">12.0</td><td colspan="1" rowspan="1">10.2</td><td colspan="1" rowspan="1">0.809&#160;&#160;[0.644-1.016]</td><td colspan="1" rowspan="1">0.0673</td></tr><tr><td colspan="1" rowspan="1"><b>with SCC (n=347)</b></td><td colspan="1" rowspan="1">10.2</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">0.794&#160;&#160;[0.626-1.007]</td><td colspan="1" rowspan="1">0.0567</td></tr><tr><td colspan="1" rowspan="1"><b>Asians (n=121)</b></td><td colspan="1" rowspan="1">17.6</td><td colspan="1" rowspan="1">20.4</td><td colspan="1" rowspan="1">1.179&#160;&#160;[0.730- 1.905]</td><td colspan="1" rowspan="1">0.4992</td></tr><tr><td colspan="5" rowspan="1"><table-wrap foot="">HR, hazard ratio</table-wrap></td></tr></tbody></table></p></h4></td></tr></tbody></table><br/><br/>

[此贴子已经被作者于2008-6-5 9:07:08编辑过]
有爱,就有奇迹!
您需要登录后才可以回帖 登录 | 中文注册

本版积分规则

QQ|关于我们|隐私服务条款|小黑屋|手机版|91奇迹 ( 京ICP备2020048145号-6 )

GMT+8, 2024-11-24 11:47 , Processed in 0.058904 second(s), 12 queries .

Powered by Discuz! X3.4

Copyright © 2001-2023, Tencent Cloud.

快速回复 返回顶部 返回列表